{"id":"abt-493-coformulated-with-abt-530","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL4761843","moleculeType":"Unknown","molecularWeight":"704.93"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ABT-493 inhibits the HCV NS3/4A serine protease, which is essential for viral polyprotein processing and replication. The coformulation with ABT-530, an NS5A inhibitor, provides a direct-acting antiviral (DAA) combination that targets two distinct viral proteins, improving efficacy and reducing the risk of resistance development in hepatitis C treatment.","oneSentence":"ABT-493 is a hepatitis C virus (HCV) NS3/4A protease inhibitor that blocks viral replication, coformulated with ABT-530 (an NS5A inhibitor) to enhance antiviral activity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:58:37.691Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus (HCV) infection, genotype 1-6"}]},"trialDetails":[{"nctId":"NCT02939989","phase":"PHASE3","title":"Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-11-21","conditions":"Hepatitis C Virus Infection","enrollment":33},{"nctId":"NCT02640157","phase":"PHASE3","title":"A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-12","conditions":"Chronic Hepatitis C, Hepatitis C Virus, Genotype 3 Hepatitis C Virus","enrollment":506},{"nctId":"NCT02640482","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-11","conditions":"Chronic Hepatitis C Virus (HCV) Infection","enrollment":304},{"nctId":"NCT02604017","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-10","conditions":"Chronic Hepatitis C, Hepatitis C Virus, HCV","enrollment":703},{"nctId":"NCT02636595","phase":"PHASE3","title":"The Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 4, 5, or 6 Infection (ENDURANCE-4)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-11","conditions":"Hepatitis C Virus","enrollment":121},{"nctId":"NCT02738138","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-05-17","conditions":"Hepatitis C Virus Infection, Human Immunodeficiency Virus Infection, Chronic Hepatitis C","enrollment":153},{"nctId":"NCT02692703","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-04-22","conditions":"Chronic Hepatitis C, HCV, Hepatitis C Virus","enrollment":100},{"nctId":"NCT02642432","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-12-07","conditions":"Hepatitis C Virus Infection, Chronic Hepatitis C, Compensated Cirrhosis","enrollment":146},{"nctId":"NCT01995071","phase":"PHASE2","title":"A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-11","conditions":"Chronic Hepatitis C, Hepatitis C Virus, Compensated Cirrhosis","enrollment":89},{"nctId":"NCT03222583","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced, Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-10-04","conditions":"Hepatitis C Virus (HCV)","enrollment":546},{"nctId":"NCT03235349","phase":"PHASE3","title":"Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-09-29","conditions":"Hepatitis C Virus (HCV)","enrollment":160},{"nctId":"NCT02651194","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-12","conditions":"Chronic Hepatitis C Virus (HCV) Infection","enrollment":104},{"nctId":"NCT02446717","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-04","conditions":"Chronic Hepatitis C, Hepatitis C Virus, HCV","enrollment":141}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ABT-493 also known as glecaprevir","ABT-530 also known as pibrentasvir","MAVYRET"],"phase":"phase_3","status":"active","brandName":"ABT-493 coformulated with ABT-530","genericName":"ABT-493 coformulated with ABT-530","companyName":"AbbVie","companyId":"abbvie","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ABT-493 is a hepatitis C virus (HCV) NS3/4A protease inhibitor that blocks viral replication, coformulated with ABT-530 (an NS5A inhibitor) to enhance antiviral activity. Used for Chronic hepatitis C virus (HCV) infection, genotype 1-6.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}